Abbvie Inc (NYSE: ABBV) has a price-to-earnings ratio that is above its average at 48.77x. The stock has a 36-month beta value of 0.59. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 4 as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for ABBV is 1.77B, and at present, short sellers hold a 0.77% of that float. On May 06, 2024, the average trading volume of ABBV was 5.74M shares.
ABBV) stock’s latest price update
Abbvie Inc (NYSE: ABBV)’s stock price has soared by 1.85 in relation to previous closing price of 160.81. Nevertheless, the company has seen a gain of 2.61% in its stock price over the last five trading days. The Motley Fool reported 2024-05-05 that AbbVie’s revenue grew slightly in the first quarter despite Humira losing steam. The company’s successors to Humira are proving worthy.
ABBV’s Market Performance
Abbvie Inc (ABBV) has experienced a 2.61% rise in stock performance for the past week, with a -2.45% drop in the past month, and a -2.89% drop in the past quarter. The volatility ratio for the week is 2.10%, and the volatility levels for the past 30 days are at 2.04% for ABBV.. The simple moving average for the past 20 days is -0.95% for ABBV’s stock, with a 4.10% simple moving average for the past 200 days.
ABBV Trading at -5.50% from the 50-Day Moving Average
After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.44% of loss for the given period.
Volatility was left at 2.04%, however, over the last 30 days, the volatility rate increased by 2.10%, as shares sank -3.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.33% lower at present.
During the last 5 trading sessions, ABBV rose by +2.61%, which changed the moving average for the period of 200-days by +18.96% in comparison to the 20-day moving average, which settled at $165.05. In addition, Abbvie Inc saw 5.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABBV starting from Donoghoe Nicholas, who sale 21,082 shares at the price of $176.30 back on Mar 20 ’24. After this action, Donoghoe Nicholas now owns 55,903 shares of Abbvie Inc, valued at $3,716,757 using the latest closing price.
Stewart Jeffrey Ryan, the EVP, CHIEF COMMERCIAL OFFICER of Abbvie Inc, sale 58,949 shares at $178.79 during a trade that took place back on Mar 18 ’24, which means that Stewart Jeffrey Ryan is holding 60,941 shares at $10,539,508 based on the most recent closing price.
Stock Fundamentals for ABBV
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.68 for the gross margin
The net margin for Abbvie Inc stands at 0.11. The total capital return value is set at 0.13. Equity return is now at value 55.92, with 4.20 for asset returns.
Based on Abbvie Inc (ABBV), the company’s capital structure generated 0.9 points at debt to capital in total, while cash flow to debt ratio is standing at 0.31. The debt to equity ratio resting at 9.24. The interest coverage ratio of the stock is 8.09.
Currently, EBITDA for the company is 18.1 billion with net debt to EBITDA at 3.03. When we switch over and look at the enterprise to sales, we see a ratio of 6.36. The receivables turnover for the company is 4.55for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.94.
Conclusion
To sum up, Abbvie Inc (ABBV) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
